The oncogenic role of human papillomavirus proteins

Critical Reviews in Oncogenesis

Volumn 7, Issue 1-2, 1996, Pages 1-18

  Barbosa, Miguel S ^a  

^a CELGENE CORPORATION   (United States)

Author keywords

cervical cancer; E6 and E7; immortalization; oncoproteins; transformation; tumor suppressors

Indexed keywords

ONCOPROTEIN; VIRUS PROTEIN;

CARCINOGENESIS; CELL IMMORTALIZATION; CELL TRANSFORMATION; HUMAN; PAPILLOMA VIRUS; REVIEW; TUMOR SUPPRESSOR GENE; UTERINE CERVIX CARCINOMA;

EID: 0030429183     PISSN: 08939675     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevOncog.v7.i1-2.10     Document Type: Review

References (156)

1. Androphy, E. J., N. L. Hubbert, J. T. Schiller, and D. R. Lowy: Identification of the HPV-16 E6 protein from transformed mouse cells and human cervical carcinoma cell lines. EMBO J., 6:989-992 (1987a).
2. Androphy, E. J., D. R. Lowy, and J. T. Schiller: Bovine papillomavirus E2 trans-activating gene product binds to specific sites in papillomavirus DNA. Nature, 325:70-73 (1987b).
3. Arbeit, J. M., P. M. Howley, and D. Hanahan: Chronic estrogen-induced cervical and vaginal squamous carcinogenesis in human papillomavirus type 16 transgenic mice. Proc. Natl. Acad. Sci. U.S.A., 93:2930-2935 (1996).
4. Arbeit, J. M., K. Munger, P. M. Howley, and D. Hanahan: Neuroepithelial carcinomas in mice transgenic with human papillomavirus type 16 E6/B7 ORFs. Am. J. Pathol., 142:1187-1197 (1993).
5. Arbeit, J. M., K. Munger, P. M. Howley, and D. Hanahan: Progressive squamous epithelial neoplasia in K14-human papillomavirus type 16 transgenic mice. J. Virol., 68:4358-4368 (1994).
6. Arroyo, M., S. Bagchi, and P. Raychaudhuri: Association of the human papillomavirus type 16 E7 protein with the S-phase-specific E2F-cyclin A complex. Mol. Cell. Biol., 13:6537-6546 (1993).
7. Auewarakul, P., L. Gissmann, and A. Cid-Arregui: Targeted expression of the E6 and E7 oncogenes of human papillomavirus type 16 in the epidermis of transgenic mice elicits generalized epidermal hyperplasia involving autocrine factors. Mol. Cell. Biol., 14:8250-8258 (1994).
8. Baker, C. C., W. C. Phelps, V. Lindgren, M. J. Braun, M. A. Gonda, and P. M. Howley: Structural and transcriptional analysis of human papillomavirus type 16 sequences in cervical carcinoma cell lines. J. Virol., 61:962-971 (1987).
9. Banks, L., S. C. Barnett, and T. Crook: HPV-16 E7 functions at the G1 to S phase transition in the cell cycle. Oncogene, 5:833-837 (1990a).
10. Banks, L., C. Edmonds, and K. H. Vousden: Ability of the HPV16 E7 protein to bind RB and induce DNA synthesis is not sufficient for efficient transforming activity in NIH3T3 cells. Oncogene, 5:1383-1389 (1990b).
11. Barbosa, M. S., C. Edmonds, C. Fisher, J. T. Schiller, D. R. Lowy, and K. H. Vousden: The region of the HPV E7 oncoprotein homologous to adenovirus Ela and Sv40 large T antigen contains separate domains for Rb binding and casein kinase II phosphoryration. EMBO J., 9:153-160 (1990).
12. Barbosa, M. S., D. R. Lowy, and J. T. Schiller: Papillomavirus polypeptides E6 and E7 are zinc-binding proteins. J. Virol., 63:1404-1407 (1989).
13. Barbosa, M. S., W. C. Vass, D. R. Lowy, and J. T. Schiller: In vitro biological activities of the E6 and E7 genes vary among human papillomaviruses of different oncogenic potential. J. Virol., 65:292-298 (1991).
14. Bedell, M. A., K. H. Jones, S. R. Grossman, and L. A. Laimins: Identification of human papillomavirus type 18 transforming genes in immortalized and primary cells. J. Virol., 63:1247-1255 (1989).
15. Bedell, M. A., K. H. Jones, and L. A. Laimins: The E6-E7 region of human papillomavirus type 18 is sufficient for transformation of NIH 3T3 and rat-1 cells. J. Virol., 61:3635-3640 (1987).
16. Bernard, B. A., C. Bailly, M. C. Lenoir, M. Darmon, F. Thierry, and M. Yaniv: The human papillomavirus type 18 (HPV18) E2 gene product is a repressor of the HPV 18 regulatory region in human keratinocytes. J. Virol., 63:4317-4324 (1989).
17. Blanton, R. A., M. D. Coltrera, A. M. Gown, C. L. Halbert, and J. K. McDougall: Expression of the HPV16 E7 gene generates proliferation in stratified squamous cell cultures which is independent of endogenous p53 levels. Cell. Growth Differ., 3:791-802 (1992).
18. Boyd, J. M., S. Malstrom, T. Subramanian, L. K. Venkatesh, U. Schaeper, B. Elangovan, C. D'Sa-Eipper, and G. Chinnadurai: Adenovirus E1B 19 kDa and Bcl-2 proteins interact with a common set of cellular proteins [see comments] [published erratum appears in Cell, 79(6): following 1120]. Cell, 79:341-351 (1994).
19. Burkhardt, A., D. DiMaio, and R. Schlegel: Genetic and biochemical definition of the bovine papillomavirus E5 transforming protein. EMBO J., 6:238-2385 (1987).
20. Burkhardt, A., M. Willingham, C. Gay, K. T. Jeang, and R. Schlegel: The E5 oncoprotein of bovine papillomavirus is oriented asymmetrically in Golgi and plasma membranes. Virology, 170:334-339 (1989).
21. Chellappan, S., S. Hiebert, M. Mudryl, J. Horowitz, and J. Nevins: The E2F transcription factor is a cellular target for the RB protein. Cell, 65:1053-1061 (1991).
22. Chen, J. J., C. E. Reid, V. Band, and E. J. Androphy: Interaction of papillomavirus E6 oncoproteins with a putative calcium-binding protein. Science, 269:529-531 (1995).
23. Chiang, C.-M., M. Ustav, A. Stenlund, T. F. Ho, T. R. Broker, and L. T. Chow: Viral E1 and E2 proteins support replication of homologous and heterologous papillomaviral origins. Proc. Natl. Acad. Sci. U.S.A., 89:5799-5803 (1992).
24. Cobrinik, D., P. Whyte, D. S. Peeper, T. Jacks, and R. A. Weinberg: Cell cycle-specific association of E2F with the p130 E1A-binding protein. Genes Dev., 7:2392-2404 (1993).
25. Comerford, S. A., S. D. Maika, L. A. Laimins, A. Messing, H. P. Elsasser, and R. E. Hammer: E6 and E7 expression from the HPV 18 LCR: development of genital hyperplasia and neoplasia in transgenic mice. Oncogene, 10:587-597 (1995).
26. Crook, T., J. A. Tidy, and K. H. Vousden: Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation. Cell, 67:547-556 (1991).
27. Dalal, S., Q. Gao, E. J. Androphy, and V. Band: Mutational analysis of human papillomavirus type 16 E6 demonstrates that p53 degradation is necessary for immortalization of mammary epithelial cells. J. Virol., 70:683-688 (1996).
28. Davies, R., R. Hicks, T. Crook, J. Morris, and K. Vousden: Human papillomavirus type 16 E7 associates with a histone H1 kinase and with p107 through sequences necessary for transformation. J. Virol., 67:2521-2528 (1993).
29. Deau, M. C., M. Favre, and G. Orth: Genetic heterogeneity among human papillomaviruses (HPV) associated with epideimodysplasia verruciformis: evidence for multiple allelic forms of HPV5 and HPV8 E6 genes. Virology, 184:492-503 (1991).
30. Demeret, C., M. Yaniv, and F. Thierry: The E2 transcriptional repressor can compensate for Sp1 activation of the human papillomavirus type 18 early promoter. J. Virol., 68:7075-7082 (1994).
31. Desaintes, C., S. Hallez, P. Van Alphen, and A. Burny: Transcriptional activation of several heterologous promoters by the E6 protein of human papillomavirus type 16. J. Virol., 66:325-333 (1992).
32. Dollard, S. C., J. L. Wilson, L. M. Demeter, W. Bonnez, R. C. Reichman, T. R. Broker, and L. T. Chow: Production of human papillomavirus and modulation of the infectious program in epithelial raft cultures. Genes Dev., 6:1131-1142 (1992).
33. Dostatni, N., P. F. Lambert, R. Sousa, J. Ham, P. M. Howley, and M. Yaniv: The functional BPV-1 E2 trans-activating protein can act as a repressor by preventing formation of the initiation complex. Genes Dev., 5:1657-1671 (1991).
34. Drummond-Barbosa, D. A., R. R. Vaillancourt, A. Kazlauskas, and D. DiMaio: Ligand-independent activation of the platelet-derived growth factor beta receptor: requirements for bovine papillomavirus E5-induced mitogenic signaling. Mol. Cell. Biol., 15:2570-2581 (1995).
35. Dyson, N., M. Dembski, A. Fattaey, C. Ngwu, M. Ewen, and K. Helin: Analysis of p107-associated proteins: p107 associates with a form of E2F that differs from pRB-associated E2F-1. J. Virol., 67:7641-7647 (1993).
36. Dyson, N., P. Guida, K. Munger, and E. Harlow: Homologous sequences in adenovirus E1A and human papillomavirus E7 proteins mediate interaction with the same set of cellular proteins. J. Virol., 66:6893-6902 (1992).
37. Dyson, N., P. M. Howley, K. Munger, and E. Harlow: The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science, 243:934-937 (1989).
38. El-Deiry, W. S., T. Tokino, V. E. Velculescu, D. B. Levy, R. Parsons, J. M. Trent, D. Lin, W. E. Mercer, K. W. Kinzler, and B. Vogelstein: WAF-1, a potential mediator of p53 tumor suppression. Cell, 75:817-825 (1993).
39. Firzlaff, J. M., D. A. Galloway, R. N. Eisenman, and B. Luscher. The E7 protein of human papillomavirus type 16 is phosphorylated by casein kinase II. New Biol., 1:44-53 (1989).
40. Firzlaff, J. M., B. Luscher, and R. N. Eisenman: Negative charge at the casein kinase u phosphorylation site is important for transformation but not for Rb protein binding by the E7 protein of human papillomavirus type 16. Proc. Natl. Acad. Sci. U.SA., 88:5187-5191 (1991).
41. Foster, S. A., G. W. Demers, B. G. Etscheid, and D. A. Galloway: The ability of human papillomavirus E6 proteins to target p53 for degradation in vivo correlates with their ability to abrogate actinomycin D-induced growth arrest. J. Virol., 68:5698-5705 (1994).
42. Frattini, M. G., H. B. Lim, and L. A. Laimins: In vitro synthesis of oncogenic human papillomaviruses requires episomal genomes for differentiation-dependent late expression. Proc. Natl. Acad. Sci. U.S.A., 93:3062-3067 (1996).
43. Gage, J. R., C. Meyers, and F. O. Wettstein: The E7 proteins of the nononcogenic human papillomavirus type 6b (HPV-6b) and of the oncogenic IIPV-16 differ in retinoblastoma protein binding and other properties. J. Virol., 64:723-730 (1990).
44. Galloway, D. A.: Human papillomavirus vaccines: a warty problem. Infect. Agents Dis., 3:187-193 (1994).
45. Gius, D., S. Grossman, M. A. Bedell, and L. A. Laimins: Inducible and constitutive enhancer domains in the noncoding region of human papillomavirus type 18. J. Virol., 62:665-672 (1988).
46. Greenfield, I., J. Nickerson, S. Penman, and M. Stanley: Human papillomavirus 16 E7 protein is associated with the nuclear matrix. Proc. Natl. Acad. Sci. U.S.A., 88:11217-11221 (1991).
47. Greenhalgh, D. A., X. J. Wang, A. M. Dominey, J. A. Rothnagel, and D. R. Roop: Development of transgenic mouse models of skin carcinogenesis: potential applications. Prog. Clin. Biol. Res., 387:75-94 (1994).
48. Griep, A. E., R. Herber, S. Jeon, J. K. Lohse, R. R. Dubielzig, and P. F. Lambert: Tumorigenicity by human papillomavirus type 16 E6 and E7 in transgeriic mice correlates with alterations in epithelial cell growth and differentiation. J. Virol., 67:1373-1384 (1993).
49. Grossman, S. R. and L. A. Laimins: E6 protein of human papillomavirus type 18 binds zinc. Oncogene, 4:1089-1093 (1989).
50. Halbert, C. L., G. W. Demers, and D. A. Galloway: The E6 and E7 genes of human papillomavirus type 6 have weak immortalizing activity in human epithelial cells. J. Virol., 66:2125-2134 (1992).
51. Hashida, T. and S. Yasumoto: Casein kinase II activities related to hyperphosphorylation of human papillomavirus type 16-E7 oncoprotein in epidermal keratinocytes. Biochem. Biophys. Res. Commun., 172:958-964 (1990).
52. Hashida, T. and S. Yasumoto: Induction of chromosome abnormalities in mouse and human epidermal keratinocytes by the human papillomavirus type 16 E7 oncogene. J. Gen. Virol., 72:1569-1577 (1991).
53. Haugen, T. H., T. P. Cripe, G. D. Ginder, M. Karin, and L. P. Turek: Trans-activation of an upstream early gene promoter of bovine papillomavirus-1 by a product of the viral E2 gene. EMBO J., 6:145-152 (1987).
54. Hawley-Nelson, P., K. H. Vousden, N. L. Hubbert, D. R. Lowy, and J. T. Schiller: HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes. EMBO J., 8:3905-3910 (1989).
55. Hecht, J. L., A. S. Kadish, G. Jiang, and R. D. Burk: Genetic characterization of the human papillomavirus (HPV) 18 E2 gene in clinical specimens suggests the presence of a subtype with decreased oncogenic potential. Int. J. Cancer, 60:369-376 (1995).
56. Heck, D. V., C. L. Yee, P. M. Howley, and K. Munger: Efficiency of binding the retinoblastoma protein correlates with the transforming capacity of the E7 oncoproteins of the human papillomaviruses. Proc. Natl. Acad. Sci. U.S.A., 89:4442-4446 (1992).
57. Herber, R., A. Liem, H. Pilot, and P. F. Lambert: Squamous epithelial hyperplasia and carcinoma in mice transgenic for the human papillomavirus type 16 E7 oncogene. J. Virol., 70:1873-1881 (1996).
58. Holt, S. E., L. S. Gollahon, T. Willingham, M. S. Barbosa, and J. W. Shay: p53 levels in human mammary epithelial cells expressing wild-type and mutant human papillomavirus type 16 (HPV-16) E6 proteins: relationship to reactivation of telomerase and immortalization. Int. J. Oncol., 8:263-270 (1996).
59. Howes, K. A., N. Ransom, D. S. Papermaster, J. G. Lasudry, D. M. Albert, and J. J. Windle: Apoptosis or retinoblastoma: alternative fates of photoreceptors expressing the HPV-16 E7 gene in the presence or absence of p53 [published erratum appears in Genes Dev., 8(14):1738 (1994)]. Genes Dev., 8:1300-1310 (1994).
60. Howley, P. M.: Papillomavirinae and their replication. In: Fundamental Virology (B. N. Fields and D. M . Knipe, Eds.) Raven Press, New York, 1625-1650 (1991).
61. Hu, T., S. C. Ferril, A.-M. Snider, and M. S. Barbosa: In vivo analysis of HPV E7 protein association with pRb, p 107 and p130. Int. J. Oncol., 6:167-174 (1995).
62. Hubbert, N. L., S. A. Sedman, and J. T. Schiller: Human papillomavirus type 16 E6 increases the degradation rate of p53 in human keratinocytes. J. Virol., 66:6237-6241 (1992).
63. Huibregtse, J. M., M. Scheffner, S. Beaudenon, and P. M. Howley: A family of proteins structurally and functionally related to the E6-AP ubiquitin-protein ligase [published erratum appears in Proc. Natl. Acad. Sci. U.S.A., 92(11):5249 (1995)]. Proc. Natl. Acad. Sci. U.S.A., 92:2563-2567 (1995).
64. Huibregtse, J. M., M. Scheffner, and P. M. Howley: A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16. or 18. EMBO J., 10:4129-4135 (1991).
65. Huibregtse, J. M., M. Scheffner, and P. M. Howley: Cloning and expression of the cDNA for E6-AP, a protein that mediates the interaction of the human papillomavirus E6 oncoprotein with p53. Mol. Cell. Biol., 13:775-784 (1993a).
66. Huibregtse, J. M., M. Scheffner, and P. M. Howley: Localization of the E6-AP regions that direct human papillomavirus E6 binding, association with p53, and ubiquitination of associated proteins. Mol. Cell. Biol., 13:4918-4927 (1993b).
67. Huibregtse, J. M., M. Scheffner, and P. M. Howley: E6-AP directs the HPV E6-dependent inactivation of p53 and is representative of a family of structurally and functionally related proteins. Cold Spring Harb. Symp. Quant. Biol., 59:237-245 (1994).
68. Hunter, T. and J. Pines: Cyclins and cancer H: cyclin D and CDK inhibitors come of age. Cell, 79:573-582 (1994).
69. Imai, Y., Y. Matsushima, T. Sugimura, and M. Terada: Purification and characterization of human papillomavirus type 16 E7 protein with preferential binding capacity to the underphosphorylated form of retinoblastoma gene product. J. Virol., 65:4966-4972 (1991).
70. Jenison, S. A., X. P. Yu, J. M. Valentine, L. A. Koutsky, A. E. Christiansen, A. M. Beckmann, and D. A. Galloway: Evidence of prevalent genital-type human papillomavirus infections in adults and children. J. Infect. Dis., 162:60-69 (1990).
71. Jeon, S. and P. F. Lambert: Integration of human papillomavirus type 16 DNA into the human genome leads to increased stability of E6 and E7 mRNAs: implications for cervical carcinogenesis, Proc. Natl. Acad. Sci. U.S.A., 92:1654-1658 (1995).
72. Jewers, R. J., P. Hildebrandt, J. W. Ludlow, B. Kell, and D. J. McCance: Regions of human papillomavirus type 16 E7 oncoprotein required for immortalization of human keratinocytes. J. Virol., 66:1329-1335 (1992).
73. Jones, R. E., R. J. Wegrzyn, D. R. Patrick, N. L. Balishin, G. A. Vuocolo, M. W. Riemen, D. Defeo-Jones, V. M. Garsky, D. C. Heimbrook, and A. Oliff. Identification of HPV-16 E7 peptides that are potent antagonists of E7 binding to the retinoblastoma suppressor protein. J. Biol. Chem., 265:12782-12785 (1990).
74. Kaelin Jr., W., M. Ewen, and D. Livingston: Definition of the minimal simian virus 40 large T antigen-and adenovirus EIA-binding domain in the retinoblastoma gene product. Mol. Cell. Biol., 10:3761-3769 (1990).
75. Kanda, T., A. Furuno, and K. Yoshiike: Human papillomavirus type 16 open reading frame E7 encodes a transforming gene for rat 3Y1 cells. J. Virol., 62:610-613 (1988).
76. Klingelhultz, A. J., S. A. Foster, and J. K. McDougall: Telomerase activation by the E6 gene product of human papillomavirus type 16. Nature, 380:79-82 (1996).
77. Kondoh, G., Y. Murata, K. Aozasa, M. Yutsudo, and A. Hakura: Very high incidence of germ cell tumorigenesis (seminomagenesis) in human papillomavirus type 16 transgenic mice. J. Virol., 65:3335-3339 (1991).
78. Laimins, L. A.: The biology of human papillomaviruses: from warts to cancer. Infect. Agents Dis., 2:74-86 (1993).
79. Lam, E. W., J. D. Morris, R. Davies, T. Crook, R. J. Watson, and K. H. Vousden: HPV16 E7 oncoprotein deregulates B-myb expression: correlation with targeting of p107/E2F complexes. EMBO J., 13:871-878 (1994).
80. Lambert, P. F.: Papillomavirus DNA replication. J. Virol., 65:3417-3420 (1991).
81. Lambert, P. F., H. Pan, H. C. Pilot, A. Liem, M. Jackson, and A. E. Griep: Epidermal cancer associated with expression of human papillomavirus type 16 E6 and E7 oncogenes in the skin of transgenic mice. Proc. Natl. Acad. Sci. U.S.A., 90:5583-5587 (1993).
82. Lamberti, C., L. C. Morrissey, S. R. Grossman, and E. J. Androphy: Transcriptional activation by the papillomavirus E6 zinc finger oncoprotein. EMBO J., 9:1907-1913 (1990).
83. Larsen, P. M., L. Storgaard, and S. J. Fey: Proteins present in bovine papillomavirus particles. J. Virol., 61:3596-3601 (1987).
84. Lowy, D. R., R. Kirnbauer, and J. T. Schiller: Genital human papillomavirus infection. Proc. Natl. Acad. Sci. U.S.A., 91:2436-2440 (1994).
85. Ludlow, J. W., J. A. DeCaprio, C. M. Huang, W. H. Lee, E. Paucha, and D. M. Livingston: SV40 large T antigen binds preferentially to an underphosphorylated member of the retinoblastoma susceptibility gene product family. Cell, 56:57-65 (1989).
86. Martin, P., W. C. Vass, J. T. Schiller, D. R. Lowy, and T. J. Velu: The bovine papillomavirus E5 transforming protein can stimulate the transforming activity of EGF and CSF-1 receptors. Cell, 59:21-32 (1989).
87. Matlashewski, G., J. Schneider, L. Banks, N. Jones, A. Murray, and L. Crawford: Human papillomavirus type 16 DNA cooperates with activated ras in transforming primary cells. EMBO J., 6:1741-1740 (1987).
88. Matsukura, T., T. Kanda, A. Furuno, H. Yoshikawa, T. Kawana, and K. Yoshiike: Cloning of monomeric human papillomavirus type 16 DNA integrated within cell DNA from a cervical carcinoma. J. Virol., 58:979-982 (1986).
89. McCance, D. J., R. Kopan, E. Fuchs, and L. A. Laimins: Human papillomavirus type 16 alters human epithelial cell differentiation in vitro. Proc. Natl. Acad. Sci. U.S.A., 85:7169-7173 (1988).
90. McIntyre, M. C., M. N. Ruesch, and L. A. Laimins: Human papillomavirus E7 oncoproteins bind a single form of cyclin E in a complex with cdk2 and p107. Virology, 215:73-82 (1996).
91. Meyers, C., M. G. Frattini, J. B. Hudson, and L. A. Laimins: Biosynthesis of human papillomavirus from a continuous cell line upon epithelial differentiation. Science, 257:971-973 (1992).
92. Mitrani-Rosenbaum, S., R. Tsvieli, and R. Tur-Kaspa: Oestrogen stimulates differential transcription of human papillomavirus type 16 in SiHa cervical carcinoma cells. J. Genet. Virol., 70:2227-2232 (1989).
93. Mohr, I. J., R. Clark, S. Sun, E. J. Androphy, P. MacPherson, and M. R. Botchan: Targeting the E1 replication protein to the papillomavirus origin of replication by complex formation with the E2 transactivator. Science, 250:1694-1699 (1991).
94. Moskaluk, C. A. and D. Bastia: The E2 "gene" of bovine papillomaviras encodes an enhancer binding protein. Proc. Natl. Acad. Sci. U.S.A., 84:1215-1218 (1987).
95. Muller, M., L. Gissmann, R. J. Cristiano, X. Y. Sun, I. H. Frazer, A. B. Jenson, A. Alonso, H. Zentgraf, and J. Zhou: Papillomavirus capsid binding and uptake by cells from different tissues and species. J. Virol., 69:948-954 (1995).
96. Munger, K., W. C. Phelps, V. Bubb, P. M. Howley, and R. Schlegel: The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J. Virol., 63:4417-4421 (1989a).
97. Munger, K., B. A. Werness, N. Dyson, W. C. Phelps, E. Harlow, and P. M. Howley: Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. EMBO J., 8:4099-4105 (1989b).
98. Munger, K., C. L. Yee, W. C. Phelps, J. A. Pietenpol, H. L. Moses, and P. M. Howley: Biochemical and biological differences between E7 oncoproteins of the high- and low-risk human papillomavirus types are determined by amino-terminal sequences. J. Virol, 65:3943-3948 (1991).
99. Nilson, L. A. and D. DiMaio: Platelet-derived growth factor receptor can mediate tumorigenic transformation by the bovine papillomavirus E5 protein. Mol. Cell. Biol., 13:4137-4145 (1993).
100. Pagano, M., M. Durst, S. Joswig, G. Draetta, and P. Jansen-Durr: Binding of the human transcription factor to the retinoblastoma protein but not cyclin A is abolished in HPV- 16-immortalized cells. Oncogene, 7:1681-1686 (1992).
101. Pan, H. and A. E. Griep: Altered cell cycle regulation in the lens of HPV-16 E6 or E7 transgenic mice: implications for tumor suppressor gene function in development. Genes Dev., 8:1285-1299 (1994).
102. Pan, H. and A. E. Griep: Temporally distinct patterns of p53-dependent and p53-independent apoptosis during mouse lens development. Genes Dev., 9:2157-2169 (1995).
103. Pater, M. M., R. Mittal, and A. Pater: Role of steroid hormones in potentiating transformation of cervical cells by human papillomaviruses. Trends Microbiol., 2:229-235 (1994).
104. Patrick, D. R., A. Oliff, and D. C. Heimbrook: Identification of a novel retinoblastoma gene product binding site on human papillomavirus type 16 E7 protein. J. Biol. Chem., 269:6842-6850 (1994).
105. Petti, L., L. A. Nilson, and D. DiMaio: Activation of the platelet-derived growth factor receptor by the bovine papillomavirus E5 transforming protein. EMBO J., 10:845-855 (1991).
106. Phelps, W. C., K. Munger, C. L. Yee, J. A. Barnes, and P. M. Howley: Structure-function analysis of the human papillomavirus type 16 E7 oncoprotein. J. Virol., 66:2418-2427 (1992).
107. Phelps, W. C., C. L. Yee, K. Munger, and P. M. Howley: The human papillomavirus type 16 E7 gene encodes transactivation and transformation functions similar to those of adenovirus E1A. Cell, 53:539-547 (1988).
108. Pietenpol, J. A., R. W. Stein, E. Moran, P. Yaciuk, R. Schlegel, R. M. Lyons, M. R. Pittelkow, K. Munger, P. M. Howley, and H. L. Moses: TGF-beta 1 inhibition of c-myc transcription and growth in keratinocytes is abrogated by viral transforming proteins with pRB binding domains. Cell, 61:777-785 (1990).
109. Riese, D. J. N. and D. DiMaio: An intact PDGF signaling pathway is required for efficient growth transformation of mouse C127 cells by the bovine papillomavirus E5 protein. Oncogene, 10:1431-1439 (1995).
110. Roberts, S., I. Ashmole, L. J. Gibson, S. M. Rookes, G. J. Barton, and P. H. Gallimore: Mutational analysis of human papillomavirus E4 proteins: identification of structural features important in the formation of cytoplasmic E4/cytokeratin networks in epithelial cells. J. Virol., 68:6432-6445 (1994).
111. Roberts, S., I. Ashmole, G. D. Johnson, J. W. Kreider, and P. H. Gallimore: Cutaneous and mucosal human papillomavirus E4 proteins form intermediate filament-like structures in epithelial cells. Virology, 197:176-187 (1993).
112. Roden, R. B., R. Kirnbauer, A. B. Jenson, D. R. Lowy, and J. T. Schiller: Interaction of papillomaviruses with the cell surface. J. Virol., 68:7260-7266 (1994).
113. Roth, E. J., B. Kurz, L. Liang, C. L. Hansen, C. T. Dameron, D. R. Winge, and D. Smotkin: Metal thiolate coordination in the E7 proteins of human papilloma virus 16 and cottontail rabbit papilloma virus as expressed in Escherichia coli. J. Biol. Chem., 267:16390-16395 (1992).
114. Sang, B. C. and M. S. Barbosa: Single amino acid substitutions in low-risk human papillomavirus (HPV) type 6 E7 protein enhance features characteristic of the high-risk HPVE7 oncoproteins. Proc. Natl. Acad. Sci. U.S.A., 89:8063-8067 (1992).
115. Sarnow, B.: Adenovirus E1b-58Kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54Kd cellular protein in trasformed cell. Cell, 28:387-394 (1982).
116. Sasagawa, T., G. Kondoh, M. Inoue, M. Yutsudo, and A. Hakura: Cervical/vaginal dysplasias of transgenic mice harbouring human papillomavirus type 16 E6-E7 genes. J. Gen. Virol., 75:3057-3065 (1994).
117. Sato, H., S. Watanabe, A. Furuno, and K. Yoshiike: Human papillornavirus type 16 E7 protein expressed in Escherichia coli and monkey COS-1 cells: immunofluorescence detection of the nuclear E7 protein. Virology, 170:311-315 (1989).
118. Scheffner, M., J. M. Huibregtse, and P. M. Howley: Identification of a human ubiquitin-conjugating enzyme that mediates the E6 AP-dependent ubiquitination of p53. Proc. Natl. Acad. Sci. U.S.A., 91:8797-8801 (1994).
119. Scheffner, M., J. M. Huibregtse, R. D. Vierstra, and P. M. Howley: The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell, 75:495-505 (1993).
120. Scheffner, M., B. A. Werness, J. M. Huibregtse, A. J. Levine, and P. M. Howley: The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell, 63:1129-1136 (1990).
121. Schiffman, M. H., H. M. Bauer, R. N. Hoover, A. G. Glass, D. M. Cadell, B. B. Rush, D. R. Scott, M. E. Sherman, R. J. Kurman, S. Wacholder, C. K. Stanton, and M. M. Manos: Epidemiological evidence showing that human papillomavirus infection causes most intraepithelial neoplasia. J. Natl. Cancer Inst., 85:958-964 (1993).
122. Schlegel, R., W. C. Phelps, Y. L. Zhantig, and M. Barbosa: Quantitative keratinocyte assay detects two biological activities of human papillomavirus DNA and identifies viral types associated with cervical carcinoma. EMBO J., 7:3181-3187 (1988).
123. Schlegel, R., M. Wade-Glass, M. S. Rabson, and Y. C. Yang: The E5 transforming gene of bovine papillomavirus encodes a small, hydrophobic polypeptide. Science, 233:464-467 (1986).
124. Schmitt, A., A. Rochat, R. Zeltner, L. Borenstein, Y. Barrandon, F. O. Wettstein, and F. Iftner: The primary target cells of the high-risk cottontail rabbit papillomavirus colocolize with hair follicle stem cells. J. Virol., 70:1912-1922 (1996).
125. Schneider-Maunoury, S., O. Croissant, and G. Orth: Integration of human papillomavirus type 16 DNA sequences: a possible early event in the progression of genital tumors. J. Virol., 61:3295-3298 (1987).
126. Schwarz, E., U. K. Freese, L. Gissmann, W. Mayer, B. Roggenbuck, A. Stremlau, and H. zur Hausen: Structure and transcription of human papillomavirus sequences in cervical carcinoma cells. Nature, 314:111-114 (1985).
127. Sedman, S. A., M. S. Barbosa, W. C. Vass, N. L. Hubbert, J. A. Haas, D. R. Lowy, and J. T. Schiller: The full-length E6 protein of human papillomavirus type 16 has transforming and trans-activating activities and cooperates with E7 to immortalize keratinocytes in culture. J. Virol., 65:4860-4866 (1991).
128. Sedman, S. A., N. L. Hubbert, W. C. Vass, D. R. Lowy, and J. T. Schiller: Mutant p53 can substitute for human papillomavirus type 16 E6 in immortalization of human keratinocytes but does not have E6-associated transactivation or transforming activity. J. Virol., 66:4201-4208 (1992).
129. Shay, J. W.: Aging and cancer: are telomeres and telomerase the connection? Mol. Med. Today, 1:378-384 (1995).
130. Shay, J. W., W. E. Wright, D. Brasiskyte, and B. A. Van der Haegen: E6 of human papillomavirus type 16 can over-come the M1 stage of immortalization in human mammary epithelial cells but not in human fibroblasts. Oncogene, 8:1407-1413 (1993).
131. Sherman, L. and R. Schlegel: Serum- and calcium-induced differentiation of human keratinocytes is inhibited by the E6 oncoprotein of human papillomavirus type 16. J. Virol., 70:3269-3279 (1996).
132. Srnotkin, D., H. Prokoph, and F. O. Wettstein: Oncogenic and nononcogenic human genital papillomaviruses generate the E7 mRNA by different mechanisms. J. Virol., 63:1441-1447 (1989).
133. Smotkin, D. and F. O. Wettstein: Transcription of human papillomavirus type 16 early genes in a cervical cancer and a cancer-derived cell line and identification of the E7 protein. Proc. Natl. Acad. Sci. U.S.A., 83:4680-4684 (1986).
134. Smotkin, D. and F. O. Wettstein: The major human papillomavirus protein in cervical cancers is a cytoplasmic phosphoprotein. J. Virol., 61:1686-1689 (1987).
135. Spalholz, B. A., Y.-C. Yang, and P. M. Howley: Transactivation of a bovine papilloma virus transcriptional regulatory element by the E2 gene product. Cell, 42:183-191 (1992).
136. Stoler, M. H., A. Whitbeck, S. M. Wolinsky, T. R. Broker, L. T. Chow, M. K. Howett, and J. W. Kreider: Infections cycle of human papillomavirus type 11 in human foreskin xenografts in nude mice. J. Virol., 64:3310-3318 (1990).
137. Storey, A., N. Almond, K. Osborn, and L. Crawford: Muta tions of the human papillomavirus type 16 E7 gene that affect transformation, transactivation and phosphorylation by the E7 protein. J. Gen. Virol., 71:965-970 (1990a).
138. Storey, A., K. Osborn, and L. Crawford: Co-transformation by human papillomavirus types 6 and 11. J. Genet. Virol., 71:165-171 (1990b).
139. Taichman, L. B. and R. F. LaPorta: The expression of papillomaviruses in epithelial cells. In: The Papovaviridae: The Papillomaviruses (N. P. Salzman and P. M. Howley, Eds.) Plenum Press, New York, 109-139 (1987).
140. Tommasino, M., J. P. Adamczewski, F. Carlotta, C. F. Barth, R. Manetti, M. Contorni, F. Cavalieri, T. Hunt, and L. Crawford: HPV16 E7 protein associates with the protein kinase p33CDK2 and cyclin A. Oncogene, 8:195-202 (1993).
141. Tsunokawa, Y., N. Takebe, T. Kasamatsu, M. Terada, and M. Sugimura: Transforming activity of human papillomavirus type 16 DNA sequences in a cervical cancer. Proc. Natl. Acad. Sci. U.S.A., 83:2200-2203 (1986).
142. Ustav, M. and A. Stenlund: Transient replication of BPV-1 requires two viral polypeptides encoded by the E1 and E2 open reading frames. EMBO J., 10:449-457 (1991).
143. Volpers, C., F. Unckell, P. Schirmacher, R. E. Streeck, and M. Sapp: Binding and internalization of human papillomavirus type 33 virus-like particles by eukaryotic cells. J. Virol., 69:3258-3264 (1995).
144. Vousden, K. H., J. Doniger, J. A. DiPaolo, and D. R. Lowy: The E7 open reading frame of human papillomavirus type 16 encodes a transforming gene. Oncogene Res., 3:167-175 (1988).
145. Wang, N. P., H. To, W. H. Lee, and E. Y. Lee: Tumor suppressor activity of Rb and p53 genes in human carcinoma cells. Oncogene, 8:279-288 (1993).
146. Weinberg, R. A.: The retinoblastoma protein and cell cycle control. Cell, 81:323-330 (1995).
147. Werness, B. A., A. J. Levine, and P. M. Howley: Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science, 248:76-79 (1990).
148. Wettstein, F. O.: Papillomaviruses and carcinogenic progression I: cottontail rabbit (Shope) papillomavirus. In: The Papovaviridae: The Papillomaviruses (N. P. Salzman and P. M. Howley, Eds.) Plenum Press, New York, 163-186 (1987).
149. White, A. E., E. M. Livanos, and T. D. Tlsty: Differential disruption of genomic integrity and cell cycle regulation in normal human fibroblasts by the HPV oncoproteins. Genes Dev., 8:666-677 (1994).
150. Whyte, P., K. J. Buchkovich, J. M. Horowitz, S. H. Friend, M. Raybuck, R. A. Weinberg, and E. Harlow: Association between an oncogene and an anti-oncogene: the adenovirus E1A proteins bind to the retinoblastoma gene product. Nature, 334:124-129 (1988).
151. Xiong, Y., D. Kuppuswamy, Y. Li, E. M. Livanos, M. Hixon, A. White, D. Beach, and T. D. Tltsy: Alteration of cell cycle kinase complexes in human papillomavirus E6-and E7-expressing fibroblasts precedes neoplastic transformation. J. Virol., 70:999-1008 (1996).
152. Yang, J. T., C. Z. Liu, and P. Iannaccone:The HPV 16 genome induces carcinomas and T-cell lymphomas in transgenic mice. Am. J. Pathol., 147:68-78 (1995).
153. Yasumoto, S., A. L. Burkhardt, J. Doniger, and J. A. DiPaolo:Human papillomavirus type 16 DNA-induced malignant transformation of NIH 3T3 cells. J. Virol., 57:572-577 (1986).
154. Yee, C., I. Krishna-Hewlett, C. C. Baker, R. Schlegel, and P. M. Howley:Presence and expression of human papillomavirus sequences in human cervical carcinoma cell lines. Am. J. Pathol., 119:361-366 (1985).
155. Yutsudo, M. and A. Hakura:Human papillomavirus type 17 transcripts expressed in skin carcinoma tissue of a patient with epidermodysplasia verruciformis. Int. J. Cancer,. 39:586-589 (1987).
156. zur Hausen, H. and E. M. de Villiers:Human papillomaviruses. Annu. Rev. Microbiol., 48:427-447 (1994).